Comment On: ‘One-Year Real-World Outcomes in Patients Receiving Fixed-Dosing Aflibercept for Neovascular Age-Related Macular Degeneration’

Eye - United Kingdom
doi 10.1038/eye.2017.211
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Aflibercept for Neovascular Age-Related Macular Degeneration

Cochrane Database of Systematic Reviews
2016English

Clinical Experience With Fixed Bimonthly Aflibercept Dosing in Treatment-Experienced Patients With Neovascular Age-Related Macular Degeneration

Clinical Ophthalmology
Ophthalmology
2015English

One Year Effectiveness Study of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Acta Ophthalmologica
MedicineOphthalmology
2018English

Treat-And-Extend Therapy Using Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration: 2-Year Real-World Practice Data From Slovenia

BMC Ophthalmology
MedicineOphthalmology
2018English

Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration in Patients Aged 90 Years or Older: 2-Year Visual Acuity Outcomes

Eye
MedicineArtsSensory SystemsOphthalmologyHumanities
2018English

Visual Outcomes in Patients With Neovascular Age-Related Macular Degeneration

Acta Ophthalmologica
MedicineOphthalmology
2017English

Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

Scientific Reports
Multidisciplinary
2019English

Baseline Predictors for One-Year Visual Outcomes With Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration

Ophthalmology
Ophthalmology
2013English

Comment on ‘Transitioning to Intravitreal Aflibercept Following a Previous Treat-And-Extend Dosing Regimen in Neovascular Age-Related Macular Degeneration: 24-Month Results’

Eye
MedicineArtsSensory SystemsOphthalmologyHumanities
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy